AstraZeneca Sees Emerging Market Opportunity for Forest Anti-Infective
This article was originally published in The Pink Sheet Daily
AstraZeneca's deal for Forest's Phase III ceftaroline may be ex-U.S., Canada and Japan, but it grants the Big Pharma rights in key emerging markets including China, and fills a late-stage pipeline gap.
You may also be interested in...
The EU's CHMP gave positive opinions on three new products – Novartis' glycopyrronium, AstraZeneca's ceftaroline and Takeda's teduglutide – and on a major new indication for Novartis’ everolimus (Afinitor), after its meeting on June 18-21.
LONDON - To extend its reach in emerging markets, AstraZeneca PLC today said it had signed an agreement with India's Torrent Pharmaceuticals Ltd. for the rights to sell 18 undisclosed generic drugs in nine territories
Innovation-only AstraZeneca gets the branded generics religion, at least in emerging markets.